Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Waldenstrom Macroglobulinemia 1Solid Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

Cytarabine 21Imatinib Mesylate 20venetoclax 16Azacitidine 16nilotinib 15Cyclophosphamide 15fludarabine 13Dasatinib 12blinatumomab 10Rituximab 10quizartinib 7Gemtuzumab 7Daunorubicin 7ruxolitinib 6Drug Therapy 6Clofarabine 6Bendamustine Hydrochloride 6AP 1903 reagent 6ponatinib 5fludarabine phosphate 5Whole-Body Irradiation 5Vincristine 5Mycophenolic Acid 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Dexamethasone 5vosaroxin 4revumenib 4rasburicase 4forodesine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia × CB-839 × Clear all
NCT02071927 2017-02-09

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Calithera Biosciences, Inc

Phase 1 Completed
43 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡